Close Menu
ImmunoGen announced last week the addition of Howard Pien to the company’s board of directors. Pien was formerly the chairman and CEO of Chiron from 2003 to 2006, and led the company through its acquisition by Novartis last year. Prior to joining Chiron, Pien held positions at SmithKline Beecham and its successor, GlaxoSmithKline.
 

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

In Science this week: whole-genome sequencing of single sperm cells, and more.

Mar
28
Sponsored by
Qiagen

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.  

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.